Human Insulin Market to Grow to be Valued USD 43.33 Billion by 2025
Increasing prevalence of
diabetics and advancements in healthcare technologies to drive the Global Human
Insulin Market through 2025.
According to TechSci Research report, “Global Human
Insulin Market
By Indication (Type I Diabetes, Type II Diabetes),
By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin
N), By Route of Administration (Subcutaneous, Transdermal, Nasal, Intravenous,
Oral and Others), By Type (Basal, Bolus,
Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid acting, Short-acting, Intermediate acting, Long acting, Pre-Mixed, Inhaled, Ultra-long Acting),
By Products (Insulin Pens, Insulin Pumps,
Infusion System, Injections), By Region, Forecast & Opportunities,
2025”, Global human insulin market was valued
at USD26.91 billion in 2019 is expected to grow at a steady CAGR of 8.01%
during the forecast period. Rising incidences of Type 1 diabetes in developed
as well as developing countries and increasing geriatric population to drive
the global human insulin market through 2025. Advancing medical facilities,
evolving healthcare infrastructure, and increasing disposable incomes are also
expected to propel the global human insulin market in the coming years. With
R&D rising in insulin therapeutics, many recent advancements have resulted
in new product launches with high efficacy rates, adding to the already
augmented demand for insulin.
Browse 227 Figures spread
through 311 Pages and an in-depth TOC on " Global
Human Insulin Market"
https://www.techsciresearch.com/report/human-insulin-market/4637.html
The
global human insulin market is segmented on the basis of indication, brand, route
of administration, type, onset type, products and region. Based on indication,
global human insulin market can be segregated into type I diabetes and type II
diabetes. Type I diabetes is leading the market as all the patients suffering
from Type I insulins are
consuming human insulin as the primary method of treatment.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4637
Customers can also request for 10% free customization on this report.
Some of the leading players in global human
insulin market include Nektar Therapeutics, MannKind Corporation, Novo Nordisk
A/S, Torrent Pharmaceuticals, Inc., Eli Lilly and Company, A-S Medication
Solutions, RemedyRepack Inc., Sedico Co., Pharmaceutical Company, Sanofi S.A.,
Gan & Lee Pharmaceuticals, BioGenomics Ltd., Pfizer Inc., PerkinElmer,
Merck & Co., Inc, Biocon Limited, Wockhardt Ltd., Ypsomed AG, Becton
Dickinson and Company, B. Braun Melsungen AG, Baxter International Inc., etc. In
order to expand their market share, the companies adopt various strategies including
organic and inorganic like mergers & acquisition. For instance, Eli Lilly
and Boehringer Ingelheim GmbH, the two renowned biotech & pharma companies in
the healthcare sector have joined hands to develop Basaglar (Insulin Glargine) for
better and advanced treatment of diabetic patients.
“In
terms of regional analysis, North America dominated the global human insulin
market in 2019 due to increasing cases of diabetes in countries like United
States and Canada. However, Asia-Pacific region is expected the fastest growing
region as it comprises of countries like China and India which have high prediabetic
and diabetic population. Additionally, rising awareness pertaining to the use
of human insulin in diabetes and strong distribution network of leading product
manufacturers is anticipated to positively impact the growth of the market in
the region.” said Mr. Karan Chechi, Research Director with TechSci Research, a
research based global management consulting firm.
“Global Human Insulin Market By
Indication (Type I Diabetes, Type II
Diabetes), By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera,
Afrezza, Novolin N), By Route of Administration (Subcutaneous, Transdermal,
Nasal, Intravenous, Oral and Others), By Type
(Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid acting, Short-acting,
Intermediate
acting, Long acting, Pre-Mixed, Inhaled, Ultra-long Acting), By Products (Insulin Pens, Insulin Pumps, Infusion System, Injections), By
Region, Forecast & Opportunities, 2025”, has
evaluated the future growth potential of global human insulin market and
provided statistics & information on market size, shares, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges and opportunities in global human insulin market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]